… The REDHART2 study is a single-center, randomized, placebo-controlled, double-blinded,
phase II clinical trial. Patients will be randomized in a 2:1 ratio to receive anakinra or placebo …

… Interleukin‐1 blockade in acute decompensated heart failure: a randomized, double‐blinded,
placebo‐controlled pilot study. J Cardiovasc Pharmacol. 2016; 67:544–551.…

… In conclusion, modulation of the inflammatory response with interleukin‐1 blockade is a
promising therapeutic strategy to prevent HF in patients with STEMI. The positive signal of …

… Phase II clinical trials show promising data with anakinra, recombinant IL-1 receptor
antagonist, in patients with ST-segment–elevation acute myocardial infarction or heart failure with …

… L) within 14 days of hospital discharge for decompensated HF. 52 Patients were randomized
1:1:1 to receive double blinded treatment with anakinra 100 mg subcutaneously daily for 12 …

… In brief, REDHART was a randomized, placebo-controlled, double-blinded, experimental …
2 weeks of hospitalization for acute decompensated systolic HF. Patients were randomized (1: 1…

… in heart failure symptoms as assessed by the Minnesota Living with Heart Failure …
Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in …

… blockade of interleukin-1 (IL-1) can have a favorable impact on patients with myocardial
infarction and heart failure… specific cytokine in mediating cardiac disease remains unclear. Hence…

… Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, …
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with …

… heart attack and prevents the development of heart failure [18]. Thus, interleukin‐1 (IL‐1)
blockade … The study will be double-blinded. Detailed description of operational peculiarities will …